Home Data for Merck's Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...
 

Keywords :   


Data for Merck's Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...

2016-07-22 13:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the companys investigational once-daily formulation of ISENTRESS (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg), from the ongoing Phase 3 pivotal trial called ONCEMRK. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Carmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the show data week

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
02.11Tropical Depression Thirteen-E Graphics
02.11Summary for Tropical Depression Thirteen-E (EP3/EP132024)
02.11Fragrancing Spaces with Atmos, A Smart Home Diffuser
02.11Eastern North Pacific Tropical Weather Outlook
02.11Atlantic Tropical Weather Outlook
01.11Tropical Depression Thirteen-E Forecast Discussion Number 1
01.11Tropical Depression Thirteen-E Graphics
01.11Tropical Depression Thirteen-E Wind Speed Probabilities Number 1
More »